Avalyn Pharma to present patient-focused research on inhaled therapies at ATS 2026 conference

Avalyn Pharma announced it will present two studies at the American Thoracic Society 2026 conference, focusing on patient experiences with its inhaled therapy AP01 and supportive care in pulmonary fibrosis. The presentations highlight Avalyn's commitment to incorporating patient and caregiver feedback to improve treatment usability and healthcare support. These findings support Avalyn's ongoing clinical trials of inhaled antifibrotic drugs aimed at improving lung function and reducing side effects in pulmonary fibrosis patients. The company aims to set a new standard of care with its inhaled therapies targeting rare respiratory diseases.